RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on Adverum Biotechnologies (NASDAQ:ADVM) but lowers the price target from $15 to $12.
August 13, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital analyst Luca Issi maintains a Sector Perform rating on Adverum Biotechnologies but lowers the price target from $15 to $12.
The lowered price target from $15 to $12 by RBC Capital suggests a less optimistic outlook for Adverum Biotechnologies, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100